BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 17582505)

  • 1. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
    Siegel M; Khosla C
    Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
    Grosso H; Mouradian MM
    Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of transglutaminase 2 in celiac disease pathogenesis.
    Klöck C; Diraimondo TR; Khosla C
    Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
    Song M; Hwang H; Im CY; Kim SY
    J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of tissue transglutaminase.
    Keillor JW; Apperley KY; Akbar A
    Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminase as a therapeutic target for celiac disease.
    Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
    Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
    Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
    Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors.
    Jasim MH; Rathbone DL
    J Mol Graph Model; 2018 Jan; 79():157-165. PubMed ID: 29179065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrates, inhibitors, and probes of mammalian transglutaminase 2.
    Zhuang R; Khosla C
    Anal Biochem; 2020 Feb; 591():113560. PubMed ID: 31874171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational Modulation of Tissue Transglutaminase via Active Site Thiol Alkylating Agents: Size Does Not Matter.
    Navals P; Rangaswamy AMM; Kasyanchyk P; Berezovski MV; Keillor JW
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
    PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis for Antigen Recognition by Transglutaminase 2-specific Autoantibodies in Celiac Disease.
    Chen X; Hnida K; Graewert MA; Andersen JT; Iversen R; Tuukkanen A; Svergun D; Sollid LM
    J Biol Chem; 2015 Aug; 290(35):21365-75. PubMed ID: 26160175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transglutaminase 2 undergoes a large conformational change upon activation.
    Pinkas DM; Strop P; Brunger AT; Khosla C
    PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies.
    Cardoso I; Stamnaes J; Andersen JT; Melino G; Iversen R; Sollid LM
    FEBS J; 2015 Jun; 282(11):2063-75. PubMed ID: 25808416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transglutaminase inhibitors: a patent review.
    Keillor JW; Apperley KY
    Expert Opin Ther Pat; 2016; 26(1):49-63. PubMed ID: 26560530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation and inhibition of transglutaminase 2 in mice.
    Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
    PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
    Watts RE; Siegel M; Khosla C
    J Med Chem; 2006 Dec; 49(25):7493-501. PubMed ID: 17149878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular warhead and its target: tissue transglutaminase and Celiac Sprue.
    Schuppan D; Dieterich W
    Chem Biol; 2003 Mar; 10(3):199-201. PubMed ID: 12670530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
    Hausch F; Halttunen T; Mäki M; Khosla C
    Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis.
    Wang Z; Perez M; Caja S; Melino G; Johnson TS; Lindfors K; Griffin M
    Cell Death Dis; 2013 Sep; 4(9):e808. PubMed ID: 24052076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.